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Abstract 
Brain disorders offer major challenges to medicine and to treatment innovation. This is 
because of their spectrum across inflammatory, degenerative, traumatic/ischemic and 
neoplastic nature and complex and often ill-understood aetiology. Genetic and genomic 
dissection offers new approaches to these challenges but one which is in its infancy at 
present. Here we review different aspects of the challenges facing neuro-medicine and give 
examples of where there are advances, as well as highlighting challenges to be overcome.  
We see that some disorders such as Huntington’s disease (HD) are the product of single gene 
mutations whose discovery is leading to the development of new-targeted interventions. In 
the field of neurosurgery, the identification of a number of mutations allows an elaborated 
genetic analysis of brain tumours and opens the door for individualized therapies. Psychiatric 
disorders remain the area where progress are left behind. Genetic analysis show that for 
major common disorders such as schizophrenia and depression there are no single gene 
alterations which offer options for targeted therapy development. However, new approaches 
are being developed to leverage genetic information to predict patient’s response to 
treatment.  
These recent developments hold promise for early diagnosis, follow-up by personalized 
treatments with adjusted therapeutic doses, predictable responses, reduced adverse drug 
reactions, and personal health planning. The scenario is promising but calls for challenging 
adaptations of health care and research infrastructures, encompassing legal frameworks for 
analysing large amounts of personal data, a flexible regulatory framework to correlate big 
data analyses in co-operative frameworks between academia and drug developing industry 
and finally new strategies for brain banking in order to increase the access to brain tissue.  
To make personalised medicine for brain disorders a reality, a joint effort of all relevant 
stakeholders where patient and patient organizations should play an important role, is 
required.  
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Introduction  
Brain disorders comprise a variety of complex diseases in the nervous system, which include 
psychiatric, neurological and neurosurgical conditions. As whole, brain disorders represent 
one of the greatest threats to public health [1–3]. Across Europe, millions of people of all ages 
struggle with brain disorders. These are often long-term conditions, which severely affect the 
quality of life and are frequently associated with a considerable disability and sometimes a 
reduced life expectancy.  As a result, they have an enormous impact on patients and their 
families and, more broadly, on the European economy. In Europe, the total annual cost of 
brain disorders was estimated at €798 billion in 2010, with an average cost per inhabitant of 
€5.550 [4]. As the population ages, the incidence of brain disorders increases even more and, 
therefore, the broad impact of brain disorders in the future is likely to be greater with 
important implications for the European economic growth.  
Because of their wide range, complex and often ill-understood aetiology, brain disorders are 
major challenges to medicine and treatment innovation. It is now clear that brain disorders 
have a strong genetic component, which confers susceptibility or resistance, and influences 
severity and progression of the disease. The complexity of this genetic component can vary 
greatly across brain disorders.  While some brain disorders are monogenic meaning that they 
result from mutations in one single gene, the prevalence of polygenic disorders resulting from 
the interplay of multiple genes and environmental factors is much higher. However, the 
distinction between these two extreme groups can be imprecise since even in the case of 
monogenic brain disorders co-operating  genetic or epigenetic  factors can alter several 
aspects of the disease such as onset, evolution and response to treatment [5]. In the recent 
years, the advent of the new genomic technologies offers the possibility to dissect the genetic 
or epigenetic components of brain disorders and opening the door to personalized medicine. 
The effective application of genomic findings to clinical practice holds the promise of 
determining the predisposition to disease and/or deliver 
The challenge to apply correctly genomic findings to clinical practice holds the promise of 
determining the predisposition to disease, to deliver timely targeted prevention and to tailor 
the right therapeutic strategy for the right patient at the right time. Several health care 
strategies integrate genomic information in the clinical research and practise as marker for 
diagnosis, prognosis and prevention, as well as targets for treatment [6]. In particular, the 
identification of genetic markers associated with disease, allows accurate diagnosis, prognosis 
and correlation to follow-up of the disease. Furthermore, it serves also as basis for the design 
of preventive strategies that minimize risk for developing the disease and of therapeutic 
approaches according to a person’s genetic makeup. Finally, the analysis of genomic 
information by uncovering the biological mechanisms that causes the disease can influence 
the approach of developing new drugs. Thus, a genome-based personalised medicine 
approach should play an important role in promoting health and combating brain disorders 
by completely shifting the therapeutic paradigm from “one fits all patients” and “trial-and-
error” prescription, to a personalized concept of treatment tailored to the specific genetic 
signature of the patient, “gene-tailored treatment”. Potentially, this should lead to more 
Kommentiert [NVH1]: This sentence wasn’t finished and means 
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powered clinical trials, which are able to detect expected subgroup efficacies in new drugs, 
rather than being discarded as “ineffective for all”.  
While recent advances and issues related to personalised medicine for brain disorders are 
more extensively reviewed elsewhere [7–12], in this article we have chosen few examples as 
paradigm for neurological, neurosurgical and psychiatric conditions which emphasise the 
major scientific challenges facing the discipline. In addition, we also discussed on those “brain 
specific” practical and ethical challenges, which relate to genetic/epigenetic disease 
assessment, brain banking and patient involvement. 
 
Neurological disorders: Huntington’s disease  
Huntington’s disease (HD) is characterized by a complex phenotype including motor, cognitive 
and psychiatric symptoms and signs starting at different ages and steadily worsening until 
death after around 15-25 years[13,14].. The cause is a dynamic mutation with expansion of a 
CAG repeat in the Huntingtin (HTT) gene[15], which is transcribed into an abnormal protein 
with an elongated polyglutamine tract. Polyglutamine HTT accumulates in the affected brain 
[16] and protein function is changed in multifaceted ways related to the numerous roles of 
the normal protein[17]. One way to handle with the disturbed protein is to silence HTT gene 
transcription, which leads to a decrease in abnormal protein content.  
Several strategies aimed at decreasing expression of the abnormal elongated allele HTT gene 
are the process of development in animal models with the hope that lower levels of the 
abnormal protein would rescue disturbed molecular pathways and decrease neuronal cell 
death. They include antisense oligonucleotides (ASO), interfering RNA molecules, and 
proteins modulating the transcription process. Decrease in HTT expression improves the 
symptoms and prolongs survival in HD mouse models[18,19]. Specifically HTT mRNA targeted 
ASO[20], induce its degradation by RNases and can be modified to be resistant to exonuclease 
cleavage improving their stability. After injection in the brain of HD animal models, HTT mRNA 
levels in the striatum are lowered without morphological damage[21]. A safety trial with 
intrathecally injected ASOs is underway (ClinicalTrials.gov identifier: NCT02519036). Small 
interfering RNA (siRNA) or micro interfering RNA (miRNA) bind to the abnormal HTT 
transcript, leading to its degradation by the RNA induced silencing complex with a consecutive 
decrease in mutated protein and this approach has been found to improve phenotype in 
animal models[22]. The molecule may be packaged into modified adenoviruses acting as a 
vector, and stereotactic injections of such constructs have been found to be safe in primates 
for 6 months[23]. This treatment is followed by a significant decrease in HTT mRNA as 
compared with controls.  
Such a precision treatment performed in a specific way according to gene mutation may 
further be personalized in order to target only the mutant gene transcript leaving the normal 
one untouched. This would allow expression of the normal protein with conservation of its 
multifaceted functions and a suggested protective function in the HD brain affected. Instead 
of a general silencing, such a strategy would use DNA or RNA specifically recognizing the 
elongated allele only in a selective (allele-specific) way, leading to the degradation of the 
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abnormal, elongated mRNA with a consecutive decrease in abnormal protein content. Such 
selectivity may be achieved by targeting single nucleotide polymorphisms found only on the 
abnormal allele, on top of targeting the expanded CAG repeat part.  siRNA may be designed 
to specifically target the mutant allele in a selective way, with conservation of a normal wild 
type HTT expression[24]. Patients with elongated CAG repeats, a status which will eventually 
lead to full penetrance of the disorder, may be selected to the target therapy according to the 
presence of specific single nucleotides on the allele with elongated CAG repeats[25]. Only 
patients who are homozygous at targeted single nucleotide sequence would not be candidate 
for such a personalized therapy.  
Since the single cause of HD is precisely known, and can be confirmed long before onset, this 
disorder may be considered as a paradigm for disease modifying treatment of other 
monogenic neurodegenerative disorders. Furthermore, there is a long presymptomatic 
phase, during which opportunities for a disease-modifying treatment might be tested and 
applied.  
 
Neurosurgical Disorders: Brain tumours  
Primary or intrinsic brain tumours, - glioma - arisinggliomas - arise from glia, are confined to 
the brain and carry an extremely poor prognosis which is determined by their diffusely 
infiltrative nature involving the whole brain precluding curative resection and precluding 
access to most anti-tumour drugs. The specific neurobiology of these tumours and brain 
physiology as such add significantly to the underlying oncological challenge. Nevertheless, 
apart from the underlying issue of drug delivery to the brain, a more elaborate genetic 
analysis of brain tumours allowed for an emerging thinking along the concepts of 
individualizing therapies also for brain tumour patients [26,27].   
Search for gene mutations specific to gliomas has begun already at the start of cancer 
genomics with at first oncogenes and then tumours suppressor genes being found[28,29]. 
More than 20 years ago it turned out that chromosomal 1p/19q deletions described very well 
oligodendroglial tumours and allow for therapeutic decisions which have been proven valid 
in clinical trials with more than a decade of follow up [30]. Many more specific gene mutations 
were found thereafter with the EGF-receptor mutations[31] and  IDH1/IDH2 mutations[32] 
being the most recent of these mutations. In addition epigenetic modifications as in the 
MGMT gene have shown to be relevant to the response to chemotherapeutics[33]. 
Very few of these molecular genetic discoveries have led to therapeutic opportunities, mostly 
because of lack of effective substances able to penetrate into the brain. Nevertheless, some 
current therapeutic developments are based on such genetic insights, such as the 
development of a peptide vaccination against a unique epitope of the mutated EGF-receptor, 
which led to a phase III trial in glioblastoma awaiting results in 2016 and likewise there is an 
early clinical trial effort with vaccination against a mutant IDH-1 peptide sequence. The 
determination of MGMT gene methylation has led to stratification of clinical trials and even 
categorical adaptation of temozolomide chemotherapy in elderly glioblastoma patients, a 
first step to personalized medicine[34].  
To improve the lives of those living with brain disorders,  
we advance the understanding of the healthy and diseased brain  
by bringing together Science & Society. 
 
 
 
 
European Brain Council (EBC) AISBL  
c/o Fondation Universitaire -- Rue D’Egmont, 11 -- BE-1000 Brussels   
www.braincouncil.eu  VAT nr:  BE 0864.644.340 
Meanwhile several large consortia efforts have arrived at the characterization of gene 
expression subtypes of glioblastoma and the dynamics of shifting patterns and their relation 
to therapy and prognosis but have not yet translated into clinical practice. This extends also 
into the less aggressive earlier “low grade” lesions, which may offer an even more beneficial 
opportunity for therapeutic intervention since the disease has not progressed as far [35]. It is 
becoming evident, that there is more knowledge available than adequately analysed for its 
clinical implications [36] and that large databases and appropriate bioinformatics are needed 
to correlate outcomes and treatment efficacies with gene profiles. Most advanced in that 
respect, - also for the availability of targeted drugs is the pediatric neuro-oncology with the 
medulloblastoma field [37–39]. With effective targeted agents for distinct genetic subgroups, 
survival and prognosis has been dramatically diversified/personalized. 
Only of late, with improving methods of detecting gene mutations as such or specific 
molecules derived thereof in the circulation, biomarkers have been defined  [40,41] which 
need to be taken into the rationale for clinical trials design upfront to account for subgroup 
efficacy. Condensing all genetic knowledge on intrinsic brain tumours, there are a sufficient 
number of genetic alterations known, which would allow a gene tailored personalized 
treatment.  
Psychiatry Disorders   
Psychiatric disorders remain the area where progress is slower. One of the obvious 
applications for the increased genetic understanding of all the main psychiatric disorders is 
leveraging this knowledge to understand better a patient’s likely response to treatment. 
However, due to the complexity of this group of diseases, success has been limited using 
conventional methodologies, where only small pathways around specific target genes are 
investigated. It is likely that even though there is a genetic contribution to psychiatric 
conditions, no obvious simple link will be reported between an individual gene and its 
polymorphisms or changes in gene expression, and treatment response. This may not be 
surprising in light of the complex genetic architecture of these conditions as well as the 
multitude of changes at the gene expression and protein level. Consequently, complementary 
routes addressing the question of individualizing a patient’s treatment need to be considered 
in addition to the conventional approach. An alternative approach is to base the search on 
the whole genome, thereby taking advantage of the ability to make multiple tests during the 
search for an association. The benefit of such an approach is to allow for the additive effective 
of what may be individually weak signals. This seams a reasonable approach in light of what 
is now known about the genomic structure of for example schizophrenia which is highly 
heritable, but which is a polygenic burden primarily arising from rare, disruptive mutations 
distributed across many genes [42]. 
One clear lesson from the studies on genetic risk association studies has been the need to 
generate sufficient sample sizes to be in a position to identify significant associations. To 
explore the question of treatment response is also likely to require relatively large sample 
sizes. This has proved possible in the search for genetic variants associated with response to 
lithium treatment in bipolar disorder [43]. Lithium response in 2563 patients was collected 
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and tested for genomic association, and one locus was identified which conferred in an 
independent test a significantly lower rate of relapse. If this result can be confirmed the locus 
would represent a novel genetic biomarker for lithium response, but its relatively low 
frequency within the population limits its direct clinical importance. It may still prove clinically 
relevant if further such loci could be identified and combined in an informative manner. 
Another source of potential variability in response to antipsychotic response has been 
reported to be associated with epigenetic changes in mGLU2 promoter activity as a potential 
consequence of long term treatment. Similarly, an investigation into the potential utility of 
DNA methylation changes in IL11 in predicting response to antidepressants in patients with 
Major Depressive Disorder (MDD) did show potential utility for this approach [44]. 
In view of the current progress that has been made and the clear scope for further 
improvement in the area of predicting treatment, response a number of suggestions can be 
made. Increase the power to detect signals through the increase of sample sizes. While is a 
challenge to collect large cohorts, there is a clear prospect for success based on the results 
achieved in the search for risk association signals [45]. For example, common polygenic 
variation was shown to account for at least one third of the total variation in schizophrenia 
risk, when 1 million SNPs are tested in more than 8,000 patients and 19,000 controls [42]. 
Another avenue to follow is to combine genomic datasets, that is combine genetic variation 
other types of –omic datasets e.g. DNA methylation status variation or proteomic data. This 
makes biological sense since there are many inputs into response beyond genetic. 
Bioinformatic techniques have been developed to allow the searching of these large datasets 
in an informed manner and which can uncover biologically meaningful relationships.  
Another key aspect is the limited access to the brain and the need of approaches that allow 
to acquiring the information from the periphery. In this respect, a new opportunity to 
overcome the problem of tissue availability is given by the use of epigenetic markers, which 
while reflecting what is occurring in the brain are accessible through peripheral tissues like 
blood urine and saliva. Underlining the validity of such approach, the analysis of epigenetic 
markers from the blood of patients with MDD has recently led to the identification of a 
potential target for novel antidepressant treatments [31]. Likewise there has been some 
success in identifying blood-based biomarkers which may predict schizophrenia prior to 
disease onset [46]. or dysregulation in the brain in patients with autism spectrum disorder 
[47]. 
Another area that needs to be considered is the integration of comorbidities, such as suicide 
and suicidal behaviors. Genetic and epigenetic biomarkers are beginning to be uncovered, 
such as SKA2 which has been linked to suicidal behavior and anxiety and stress [48,49]. As 
well as being developed further for its own sake, an important question is if there is any 
interaction with comorbid conditions. 
Overall, while important progresses have been made in beginning to build for individualized 
treatments for psychiatric disorders, at the same time major challenges remain along the path 
of moving treatments from the bench to clinical practice.  
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“Brain specific” Challenges for Personalized Medicine  
The ultimate goal in personalized medicine for brain disorders is to improve current patient 
care and accelerate future drug therapies. We have discussed some of the recent 
developments in this discipline that hold promise for personalized treatments with early 
diagnosis, adjusted therapeutic doses, predictable responses, reduced adverse drug 
reactions, and personal health planning. The scenario is exciting, but at the same time, this 
new approach faces crucial scientific, policy and ethical issues that need to be addressed in 
order to translate responsibly the scientific discoveries into clinical applications for the benefit 
of the patients.  
While many of those issues do not differ significantly between brain disorders and other 
therapeutic areas such as cancer, the limited access to the brain and the scarce availability of 
brain tissue is surely of utmost importance. By strictly speaking, brain tumours are part of the 
cancer field, and accordingly, the tiny advances made towards personalized medicine rely on 
the availability of tissue which has been easiest with leukemias which are consequently the 
most successfully treated oncological conditions. For many brain diseases, mostly 
degenerative or psychiatric, the acquisition of brain specimens is solely possible through brain 
banking once patients have succumbed to their disease.  
Thus, the access to human brain tissue is crucial to progress further our knowledge on the 
associations between particular genes and brain disorders, which is paramount to develop 
personalised therapies. Brain banks have been indispensable for the understanding of the 
pathology of many brain disorders, including Alzheimer’s and Parkinson’s [50] and they 
remains a powerful resource for brain research. However, brain banking faces a set of 
challenges that hampers the advance in this area. Brain banks are challenged with a decline 
in the clinical autopsy rate and scarcity of brain donors. That is because the current legal 
regulations pose obstacles to brain autopsies and many clinicians have lost clinical interest 
for brain autopsy or are reluctant to talk about post-mortem organ donation with their 
patients and relatives. To overcome this problem, donor programmes may be particularly 
effective to raise awareness among the public and to foster a dialogue with patients leading 
to an increase in autopsies and brain donations. The decrease in autopsy rates and in brain 
donations necessitates collaboration across national and state borders with establishment of 
brain network such as BrainNet Europe (http://www.brainnet-europe.org). This allows access 
to larger numbers of shared control cases and brains from patients with brain disorders. 
However, efficient networking requires the standardization of protocols, diagnostic 
procedures, and data acquisition so that samples and data are comparable. Although several 
recommendations for the operating of brain banks have been delivered, a globally accepted 
standard protocol or regulations for banking brain tissues are still missing.  
From an ethical point of view, a premortem written informed consent for brain donation is 
the undisputable way to respect the autonomous decision of potential donors. However, 
when patients or other persons die without preparing a written informed consent, it is 
conventional in most countries to request from relatives (next of kin) the presumptive will for 
a clinical autopsy or brain donation of the deceased. Because ethical and legal conditions vary 
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between countries, and because many countries that lack legal regulations act by customary 
rights, a code of conduct that satisfies the requirements of all members must be established 
in brain bank networks that collect brains from multiple countries or states. Moreover, 
particular ethical considerations are required for banking the brains of patients with 
psychiatric disorders, especially of consent issues. In these cases, potential donors should be 
encouraged to take time to make the decision to ensure that people with fluctuating decision-
making capacity are not acting on impulse.  
Finally, brain banks have the possibility to obtain more support from the public if they would 
successfully convey the advantages of their work. This may be achieved by publicizing the 
notion that brain banking is indispensable for the progress of medicine, as well as making 
brain bank procedures more transparent to the public. This awareness campaign will have to 
address problems of autopsy acceptability, misconceptions regarding the research that can 
be performed with human post-mortem tissues, the need to obtain support for brain banks 
from government sources or the private sector, as well as the need to increase the number 
of brain tissue donors.  
A large number of challenges must be addressed before personalised medicine for brain 
disorders can become a reality. Each of these challenges must be dealt with not by a single 
person or group, but by all of the stakeholders that are affected by it. In this respect, patients 
and patient organizations represent an important stakeholder in the whole process of 
Personalised Medicine. But to ensure an effective and responsible involvement of patients 
crucial information has to be provided. The most paramount being a clear, comprehensible 
explanation of the term Personalised Medicine, together with the possibilities, limitations, 
risks and consequences of this innovative approach.  
Relating to the issue of brain banking, patient organisations and specific disease focus groups 
must realize that once correlations can be made between genomic information that allows 
disease sub-classification as for “dementia” biomarkers might be developed which may 
reflect the disease in any bio-specimen taken alive. If an epigenetic change or a mutation 
happens only in the diseased brain, an awareness must be built that the adequate 
“personalized therapeutic decision” can only be made tissue based, requiring a biopsy. With 
exosomal analysis technology there is a hope that many diseases can be defined in the future 
from “liquid biopsies” but until that becomes available, much correlative work has to be 
performed between patients, academic consortional genomics or even “..omics” and pharma 
industry to personalize medicine as much as possible.  
National information points have to be implemented to assist patients in taking decision on 
their health plan or complaints. This will both protect the patients and preserve their patient 
rights, whilst also benefitting the progress made in the area. These information points should 
be organised at national level and monitored at the European level, making it possible for 
anyone to acquire the correct information in their own language but with trust, transparency 
and quality control present at all times. Relevant stakeholders should have access to 
appropriate information, to evaluate and enhance their techniques, care pathways, 
diagnostics, treatments, etc. which can then benefit all Member States, giving everyone 
access to the same personalised quality diagnosis and treatment. In the case of brain 
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disorders, areas such as medical devices [Deep Brain stimulation (DBS), Focused Ultrasound 
(FUS)], diagnostic imaging [MRI, fMRI, SPECT, PET, qEEG], should be included in neurological 
and psychiatric diagnostics and treatments.  
Patient organisations, at European and national level, are a huge asset with their extensive 
patient expertise. Their close partnership with patients puts them in a unique position in the 
whole process. Patient organisations build on trust, making it possible to gather large 
amounts of disease-specific data, inform patients about their disease, treatment, everyday 
life and give patients a voice by representing them and providing patient-centred information 
to all stakeholders. When involving patient organisations at European and national (regional) 
level, funding and recognition should be considered to support them in this role. Properly 
informed patients and patient organisations are proven beneficial to researchers and other 
stakeholders and involving them at the beginning of the process saves precious time and 
money.  
 
Conclusions  
The rapid development of genome-based technologies holds promise of an effective 
application of genetic information to the development of individualized therapies for patient 
with brain conditions.  
We are just at beginning of paradigm shift and a large number of scientific, policy and ethical 
challenges must be addressed before gene tailored treatments for brain disorders become a 
reality. Changing paradigm requires challenging adaptations of health care and research 
infrastructures, encompassing legal frameworks for analysing large amounts of personal data, 
a flexible regulatory framework to correlate big data analyses in co-operative frameworks 
between academia and drug developing industry and finally new strategies for brain banking 
in order to increase the access to brain tissue.  
A joint effort of all relevant stakeholders is required to overcome these challenges and make 
gene tailored treatment for brain disorders a reality. In this respect, patients and patient 
organisations represent an important stakeholder and should be involved at an early stage in 
the process and resourced to do so. Raising awareness for brain disorders and Personalised 
Medicine can stimulate potential healthy participants and focuses on brain disorders in a 
wider sense. An open dialogue with all stakeholders coordinated at an EU-level needs to take 
place as we try to put a framework for Personalised Medicine in place which allows scope for 
ethical questions to be addressed.  
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